Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin's lymphoma;Leitlinie für die radioimmuntherapie des CD20-positiven follikulären B-zell-non-Hodgkin-lymphoms

NuklearMedizin

Volumn 48, Issue 6, 2009, Pages 215-220

  Fischer, Manfred ^a   Grunwald F ^a   Knapp, W H ^a   Trumper L ^a   Schilling, C V ^a   Dreyling, M ^a  

^a Deutsche Gesellschaft für Nuklearmedizin ^*

Author keywords

CD20 receptors; Non Hodgkin lymphoma; Radioimmunotherapy; Yttrium 90; Zevalin

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ABDOMINAL PAIN; AFTERCARE; ASTHENIA; B CELL LYMPHOMA; CANCER REGRESSION; CHILL; COUGHING; DIZZINESS; DYSPNEA; EDEMA; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; HEADACHE; HOARSENESS; HUMAN; ISOTOPE LABELING; MEDICAL SPECIALIST; NAUSEA; PAIN; PRACTICE GUIDELINE; PRURITUS; QUALITY CONTROL; RADIOIMMUNOTHERAPY; SHIVERING; SHORT SURVEY; THROAT IRRITATION;

ANTIGENS, CD2; GERMANY; HUMANS; LYMPHOMA, B-CELL; NUCLEAR MEDICINE; QUALITY ASSURANCE, HEALTH CARE; RADIATION ONCOLOGY; RADIOIMMUNOTHERAPY;

EID: 73649085524     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0318     Document Type: Short Survey

References (9)

1. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
2. Dreyling M, Trumper L, von Schilling C et al. Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma - role of radioimmunotherapy. Ann Hematol 2007; 86: 81-87.
3. Morschhauser F, Illidge T, Huglo D et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110: 54-58.
4. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156-5164.
5. Peyrade F, Triby C, Slama B et al. Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review. Leuk Lymphoma 2008; 49: 1762-1768.
6. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
7. Witzig TE, Molina A, Gordon LI et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 1804-1810.
8. Zinzani PL, d'Amore F, Bombardieri E et al. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. Eur J Cancer 2008; 44: 366-373.
9. Zinzani PL, Tani M, Pulsoni A et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008; 9: 352-358.